Moderna climbs after $2.25 billion settlement for COVID vaccine patent dispute

Arbutus Biopharma

04/03/2026 10:13

** Shares of vaccine maker Moderna MRNA.O rise 4.6% to $52.13 premarket

** Co says it has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a COVID vaccine patent dispute

** The deal resolves all U.S. and international legal actions accusing Moderna of using lipid nanoparticle, or LNP, a delivery technology owned by Genevant and Arbutus, without permission in its COVID vaccine

** "We see Moderna moving past this litigation overhang as a positive clearing event and now the company has certainty it is well funded through multiple late-stage oncology readouts expected in 2026," William Blair analysts say

** Stock fell 29% in 2025

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))